Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Results for New Oxazolidinone Demonstrate Potency Against Superbugs

08.01.2002


Results for New Oxazolidinone Demonstrate Potency Against Gram-Positive Pathogens, including Superbugs



Unique compound AZD2563 shows promise for once-daily dosing

Chicago, IL World-wide data presented at the 41st Interscience Congress on Antimicrobial Agents and Chemotherapy (ICAAC) show that AstraZeneca`s new oxazolidinone (AZD2563) is active against Gram-positive bacteria, including multi-drug resistant strains, and may have the added convenience of potential once-daily administration. In addition, the compound is more potent in vitro than linezolid, the only oxazolidinone currently on the market.


AZD2563 is the latest oxazolidinone under early-stage development for the treatment of infection with Gram-positive bacteria, including multiple-drug resistant strains. The promising novel oxazolidinone compound is being developed by AstraZeneca, and its microbiological data have been proven world-wide.

A major public health threat is posed by strains of Gram-positive bacteria that have evolved resistance to treatment: some are now resistant to many common antibiotics Overcoming Antimicrobial Resistance. (World Health Report on Infectious Diseases 2000. WHO, 2000.) Some only respond to recently developed intravenous anti-bacterials, or physicians have to rely on older and potentially more toxic drugs. Oxazolidinones are a new class of antibiotics with a novel mode of action and proven world-wide clinical data that meet the urgent need for new therapies for a spectrum of Gram-positive infections, including multiple-drug resistant strains.

Keith Williams, Global Product Director at AstraZeneca, said "Seventeen abstracts were selected for presentation at ICAAC. These contain important new data that suggest the unique structure of AZD2563 confers potency and potential once-daily dosing. It appears likely that AZD2563 will have a vital role to play in the fight against Gram-positive infections."

These initial results indicate that AZD2563 has excellent, targeted activity against all common Gram-positive bacteria, regardless of resistance to other classes of antibiotics. In one study (Turner PJ, Wookey A, Greenhalgh JM, Eastwood M, Clarke J. Investigations into the Antibacterial Spectrum of the New Oxazolidinone AZD2563. Poster presented at ICAAC 2001. Abstract F-1024.), the effectiveness of AZD2563 was measured against 838 clinical strains of bacteria, and its level of activity was compared to 14 antibiotics, including linezolid. Principal Investigator Dr Philip Turner commented: "For the majority of strains of streptococci and staphylococci, including methicillin-resistant staphylococci, AZD2563 was more potent in vitro than linezolid. Activities against strains of enterococci and pneumococci were comparable between AZD2563 and linezolid. Oxazolidinones are likely to evolve into a highly successful, widely-used class of antibiotics. AZD2563 will be available as an oral as well as an intravenous therapy and is a useful addition to the anti-Gram-positive armamentarium.”

Another study (Eliopoulis GM, Wennersten CB, Moellering Jr RC. Comparative In Vitro Activity of the New Oxazolidinone, AZD2563, against Enterococci. Poster presented at ICAAC 2001. Abstract F-1034). reinforces the suggestion that AZD2563 has a more powerful action than linezolid against some strains of bacteria. The activity of AZD2563 against 500 clinical isolates of enterococci was compared to linezolid and eight other antibiotics. The findings indicate that AZD2563 is generally two-fold more active in vitro than linezolid against enterococci, including multi-drug resistant strains. This suggests that AZD2563 is a potent oxazolidinone.

In addition, another study (Arundel PA. The New Oxazolidinone, AZD2563: Physiologically-based Pharmacokinetic Extrapolation to Man. Poster presented at ICAAC 2001. Abstract F-1039.) indicates that AZD2563 may offer the convenience of once-daily dosing. Currently, the only oxazolidinone on the market is indicated for twice-daily dosing in adults. In vivo data from AZD2563 were used to predict the behaviour of the compound in man. Human simulations based on experimental data predicted that AZD2563 is long-acting. Lead Investigator Dr Phil Arundel commented: "The fact that AZD2563 is long-acting and potent indicates that once-daily dosing is feasible. AZD2563 shows great promise in the fight against infections, including those caused by multi-drug resistant bacteria, and I await the results of further studies with interest".

Leslie Wheeler | alphagalileo

More articles from Health and Medicine:

nachricht Custom-tailored strategy against glioblastomas
26.09.2016 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht New leukemia treatment offers hope
23.09.2016 | King Abdullah University of Science and Technology

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First-Ever 3D Printed Excavator Project Advances Large-Scale Additive Manufacturing R&D

Heavy construction machinery is the focus of Oak Ridge National Laboratory’s latest advance in additive manufacturing research. With industry partners and university students, ORNL researchers are designing and producing the world’s first 3D printed excavator, a prototype that will leverage large-scale AM technologies and explore the feasibility of printing with metal alloys.

Increasing the size and speed of metal-based 3D printing techniques, using low-cost alloys like steel and aluminum, could create new industrial applications...

Im Focus: New welding process joins dissimilar sheets better

Friction stir welding is a still-young and thus often unfamiliar pressure welding process for joining flat components and semi-finished components made of light metals.
Scientists at the University of Stuttgart have now developed two new process variants that will considerably expand the areas of application for friction stir welding.
Technologie-Lizenz-Büro (TLB) GmbH supports the University of Stuttgart in patenting and marketing its innovations.

Friction stir welding is a still-young and thus often unfamiliar pressure welding process for joining flat components and semi-finished components made of...

Im Focus: First quantum photonic circuit with electrically driven light source

Optical quantum computers can revolutionize computer technology. A team of researchers led by scientists from Münster University and KIT now succeeded in putting a quantum optical experimental set-up onto a chip. In doing so, they have met one of the requirements for making it possible to use photonic circuits for optical quantum computers.

Optical quantum computers are what people are pinning their hopes on for tomorrow’s computer technology – whether for tap-proof data encryption, ultrafast...

Im Focus: OLED microdisplays in data glasses for improved human-machine interaction

The Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP has been developing various applications for OLED microdisplays based on organic semiconductors. By integrating the capabilities of an image sensor directly into the microdisplay, eye movements can be recorded by the smart glasses and utilized for guidance and control functions, as one example. The new design will be debuted at Augmented World Expo Europe (AWE) in Berlin at Booth B25, October 18th – 19th.

“Augmented-reality” and “wearables” have become terms we encounter almost daily. Both can make daily life a little simpler and provide valuable assistance for...

Im Focus: Artificial Intelligence Helps in the Discovery of New Materials

With the help of artificial intelligence, chemists from the University of Basel in Switzerland have computed the characteristics of about two million crystals made up of four chemical elements. The researchers were able to identify 90 previously unknown thermodynamically stable crystals that can be regarded as new materials. They report on their findings in the scientific journal Physical Review Letters.

Elpasolite is a glassy, transparent, shiny and soft mineral with a cubic crystal structure. First discovered in El Paso County (Colorado, USA), it can also be...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Paper – Panacea Green Infrastructure?

30.09.2016 | Event News

HLF: From an experiment to an establishment

29.09.2016 | Event News

European Health Forum Gastein 2016 kicks off today

28.09.2016 | Event News

 
Latest News

First-Ever 3D Printed Excavator Project Advances Large-Scale Additive Manufacturing R&D

30.09.2016 | Materials Sciences

New Technique for Finding Weakness in Earth’s Crust

30.09.2016 | Earth Sciences

Cells migrate collectively by intermittent bursts of activity

30.09.2016 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>